Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a pharmaceutical company with a market capitalization of $2.64 billion and rated "GREAT" for financial health according to InvestingPro, ...

Among 2024’s notable new drugs were three approvals for antibiotic therapies: Allecra Therapeutics’ Exblifep (cefepime and enmetazobactam), Basilea Pharmaceutica’s Zevtera (ceftobiprole ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

If your symptoms are serious or your doctor thinks something else is causing them, they might recommend a prescription medicine. Most people don't need any kind of treatment for mild cold symptoms.

You’ll likely have a few cancer treatment options. Your doctor may recommend chemo, hormone, or targeted therapy. Sometimes you may receive a combination of therapies, or something else entirely.

Treatment for irritable bowel syndrome (IBS) may start with lifestyle changes like avoiding certain foods and relieving stress. If these don’t work, some medications may help relieve symptoms ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...

Rifaximin is under clinical development by Alfasigma and currently in Phase III for Collagenous Colitis. According to GlobalData, Phase III drugs for Collagenous Colitis does not have sufficient ...

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of ...

(NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN ® (rifaximin ...